Simplify, Personalize, Suppress: Novel Oral ART for HIV Management
Given persistent unmet needs in the management of virologically suppressed HIV, this program aims to strengthen clinicians’ knowledge of resistance, safety, adherence, and drug–drug interactions of current regimens and guidance on integrating novel oral regimens in development into individualized, guideline-based care.
In this activity, an expert in infectious diseases discusses novel oral antiretroviral therapy (ART) for the management of human immunodeficiency virus (HIV).
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Recognize the rationale for novel oral ART regimens in the management of virologically suppressed HIV infection
- Review the clinical impact of novel emerging oral ART regimens for patients with virologically suppressed HIV infection
- Formulate patient-centered strategies for optimizing the personalized management of oral ART for patients with virologically suppressed HIV infection
Faculty
Rajesh Gandhi, MD
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts
Accreditation, Credit, and Support
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Answers in CME and HealthHIV. Answers in CME is accredited by the ACCME to provide continuing medical education for physicians.
The Accreditation Council for Continuing Medical Education (ACCME) is recognized by the World Federation for Medical Education (WFME) as meeting globally accepted standards for CPD accreditation, ensuring that the education they accredit supports high-quality lifelong learning for healthcare professionals.
Credits/Contact Hours
Answers in CME designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Target Audience
This activity has been designed to meet the educational needs of infectious disease specialists and other HIV care providers, with a focus on those in the community setting, and other clinicians in the United States.
Media
Enduring Material
Release Date
May 22, 2026
Expiration Date
May 21, 2027
Time to Complete
30 Minutes
This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.
Answers in CME adheres to the standards and guidelines of the Accreditation Council for Continuing Medical Education (ACCME), including the Standards for Integrity and Independence in Accredited CE, and all other professional organizations, as applicable. Any individuals in a position to control the content of a CME/CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible companies within the past 24 months.
All relevant financial relationships have been mitigated prior to the commencement of the activity.
- Rajesh Gandhi, MD, has no relevant financial relationship(s) with ineligible companies to disclose.
- Planners, independent reviewers, and staff of Answers in CME have no relevant financial relationships with ineligible companies to disclose.
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use in certain jurisdictions. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our materials. No responsibility is taken for errors or omissions in our materials.
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
To receive credit, participants must complete the activity, the post-test, and the evaluation form prior to the expiration date noted below. There are no pre-requisites and there is no fee to participate in this activity or to receive credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form. Consult your professional licensing board for information about your eligibility to claim credit for participation in this educational activity. A minimum performance level of 80% is needed.
The participants of this educational activity have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Answers in CME or any of its supporters.
Other Related Trainings
Expanding Access: Models for Opt-Out Testing in Emergency Departments
This webinar will share interim data and lessons learned from the “Touch Points” opt-out testing and linkage to care initiative, and explore benefits and limitations of different models for opt-out HIV testing implementation.
HIV Treatment Innovation Module 5: Management of Treatment-Experienced Patients with HIV Drug Resistance
This module provides information on the latest strategies for managing treatment of patients with HIV drug resistance.
